With respect to the potential relevance of targeting this pathway for therapeutic purposes, the genetic and pharmacological studies demonstrated that targeting MEK5 or ERK5 may decrease the proliferation of sarcoma cells and reduce tumor progression in vivo. Here, MAP2K5 is linked to neoplasm.